About: Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19
Creator	Li, \| Ko, \| Huey-Kang Sytwu, \| Linju, B Liu, Jiunn Wang, -Tzu Yen, Men-Luh
Source	Medline; PMC; WHO
abstract	The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) has allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID‐19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Since there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID‐19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft‐vs‐host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious—including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis—as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials—including for COVID‐19—of MSCT for these diseases, with some perspectives and comment on MSCT for COVID‐19.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1002/sctm.20-0186
bibo:pmid	32526079
has license	cc-by
sha1sum (hex)	b587e795a806226c75fa4d9c0a577b63c5f49f04
schema:url	https://doi.org/10.1002/sctm.20-0186
resource representing a document's title	Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID‐19
has PubMed Central identifier	PMC7300965
has PubMed identifier	32526079
schema:publication	Stem Cells Transl Med
resource representing a document's body	covid:b587e795a806226c75fa4d9c0a577b63c5f49f04#body_text
is schema:about of	named entity 'record' named entity 'time' named entity 'MSC' named entity 'inflammatory' named entity 'Current' named entity 'insights' named entity 'MSCs' named entity 'ACCUMULATED' named entity 'HAVE' named entity 'disease' named entity 'unleashed' named entity '2004' named entity 'effective' named entity 'target' named entity 'immune' named entity 'data' named entity 'data' named entity 'candidate' named entity 'inflammatory diseases' named entity 'preclinical' named entity 'COVID-19' named entity 'pulmonary' named entity 'lung disorders' named entity 'immunomodulatory' named entity 'acute respiratory distress syndrome' named entity 'preclinical' named entity 'mesenchymal stem cells' named entity 'MSCT' named entity 'mortality rate' named entity 'preclinical' named entity 'MSCs' named entity 'inflammatory diseases' named entity 'allogeneic' named entity 'preclinical' named entity 'MSCs' named entity 'inflammatory' named entity 'There' named entity 'TNF-α' named entity 'allogeneic' named entity 'MSCT' named entity 'allogeneic' named entity 'microRNAs' named entity 'paracrine' named entity 'morbidity' named entity 'neutrophils' named entity 'regenerative medicine' named entity 'MSCT' named entity 'protein' named entity 'lung diseases' named entity 'dental pulp' named entity 'Preclinical studies' named entity 'cystic fibrosis' named entity 'viral infection' named entity 'inflammation' named entity 'young mice' named entity 'allogeneic' named entity 'alveolar macrophages' named entity 'alveolar macrophages' named entity 'immunomodulatory' named entity 'angiopoietin-1' named entity 'MSCT' named entity 'ARDS' named entity 'inflammation' named entity 'Tregs' named entity 'BMMSCs' named entity 'exosomes' named entity 'immunomodulatory' named entity 'MSCs' named entity 'infection' named entity 'mice' named entity 'MSCs' named entity 'mesenchymal stem cell' named entity 'intranasal' named entity 'sepsis' named entity 'clinical trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software